It is important to better understand the optimum doses and equivalent doses of antipsychotic drugs. Several methods to understand these relationships have been published, but all these methods have weaknesses. In this paper we present a dose-response meta-analysis which theoretically is the most appropriate method for this purpose.
O7.4. SYSTEMATIC REVIEW, META-ANALYSIS
Background: The drug-placebo differences ("effect sizes") in acute phase, randomised, double-blind trials have become smaller and smaller over the decades. In a recent meta-regression analysis, it had been shown that the degree of placebo response is the strongest predictor of drug-placebo differences. Thus, the open question now was what the predictors of placebo response are. Methods: Placebo-controlled, randomised, double-blind trials that compared any licensed antipsychotic drug with placebo were searched in multiple electronic databases, the website of the Food and Drug Administration and the clinical trial database ClinicalTrials.gov. The mean change from baseline of the PANSS or the BPRS total score from baseline to endpoint in the placebo-groups was extracted from each identified trial. The outcome was the degree of placebo response measured by the BPRS or PANSS change from baseline to endpoint. 24 patient-, and study design related parameters were analysed as potential predictors of placebo response in univariate and multivariate meta-regression analyses.
Results: Of 167 included RCTs 99 provided the necessary data. In univariate analyses more recent publication year, larger sample size (total number of participants and sites), use of PANSS rather than the BPRS, studies conducted outside the US or mixed, shorter wash-out phases and shorter study duration, lower participant mean age and lower mean duration of illness were associated with higher placebo-response. Discussion: This meta-regression included approximately two times more studies than previous attempts to resolve this issue and it is therefore the to date by far largest analysis of this kind. Multiple potential moderators of placebo response were identified. Importantly, these moderators of placebo response were not identical with those identified in a previous analysis 1 as significant moderators of drug-placebo differences in the same dataset. Thus, different factors appear to play a role in this complex area. Background: Long-term maintenance treatment is recommended to control the symptoms of schizophrenia 1,2 ; therefore, safety monitoring for longer than the period required to treat an acute exacerbation is warranted. The aim of the present study (Lighthouse extension; NCT01810783) was to assess the long-term safety and tolerability of open-label treatment with brexpiprazole (flexible dose 1-4 mg/day) in adult patients with schizophrenia. Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at the serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at the 5-HT2A and noradrenaline α1B/2C receptors, all with subnanomolar potency. Brexpiprazole is approved in the US as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) and in the US, Australia and Canada as monotherapy for treatment of schizophrenia. Methods: Patients rolled over into this 52-week open-label study from a randomized, double-blind, placebo-controlled, active referenced, Phase 3 study (Lighthouse 3 ; NCT01810380). The primary endpoint was safety and tolerability. Efficacy was assessed as an exploratory endpoint using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions -Severity of illness (CGI-S) and Improvement (CGI-I) scales, and the Personal and Social Performance (PSP) scale. Changes from baseline were analyzed using a mixed model repeated measurements (MMRM) approach. Results: 210 patients were enrolled, and 101 (48.3%) completed the study. The mean and mean modal doses of brexpiprazole were 3.07mg/day and 3.18mg/day, respectively; at last visit, 50% of the patients received 4mg/ day. Among patients who took ≥1 dose of brexpiprazole, the incidence of discontinuation due to treatment-emergent adverse events (TEAEs) was 17.2%. TEAEs with an incidence of ≥5.0% were schizophrenia
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